###### Key messages

What is already known about this subject?
=========================================

-   Human host defence peptide cathelicidin (LL-37) regulates inflammation and promotes autoimmune responses.

What does this study add?
=========================

-   Circulating LL-37 associates with anti-CCP in early inflammatory arthritis.

-   Circulating LL-37 does not associate with serum 25(OH)vitamin D or with common vitamin D receptor polymorphisms.

How might this impact on clinical practice?
===========================================

-   This suggests LL-37 may have a role in the development of inflammatory arthritis.

Dysregulated citrullination at articular and extra-articular sites leads to the generation of anti-citrullinated peptide autoantibodies in individuals with genetic susceptibility to rheumatoid arthritis (RA).[@R1] One source of citrullinated autoantigens in RA is activated neutrophils which release neutrophil extracellular traps (NETs) in response to infections and toxins.[@R2] NETs contain a high concentration of the human host defence peptide cathelicidin (LL-37)[@R3] a protein which regulates inflammation and promotes autoimmune responses.[@R4] However, it is not clear if the formation of autoantibodies to citrullinated proteins is enhanced by LL-37 in RA.

LL-37 expression can be regulated by vitamin D, which is also associated with autoimmune pathways relevant to RA.[@R9] Gene expression of hCAP18, the preproprotein of LL-37, is governed by the vitamin D/vitamin D receptor (VDR) complex.[@R10] Even though low serum vitamin D levels and VDR polymorphisms are associated with RA in some populations,[@R11] the association of vitamin D mediated expression of LL-37 with pathogenic events in RA remains unclear.

In this study we aimed to delineate the association between LL-37 with antibodies to citrullinated peptides, circulating vitamin D and VDR polymorphisms, in early inflammatory arthritis (EIA).

Methods {#s1}
=======

Study participants {#s1-1}
------------------

Participants with inflammatory arthritis for less than 1 year and naïve to disease modifying anti-rheumatic drug therapy were recruited from outpatient rheumatology clinics. Patients with RA,[@R12] undifferentiated arthritis (UA) (inflammatory arthritis not meeting criteria for defined arthropathy) or spondyloarthropathy (SpA) (predominantly psoriatic arthritis or reactive arthritis) were included. Smoking status was assessed by self-report (never, past, current smoker). Arthritis activity was assessed using the disease activity composite score (DAS28ESR3var) and function using the modified health assessment questionnaire (mHAQ).

LL37 and 25-hydroxy vitamin D (25(OH)D) {#s1-2}
---------------------------------------

Commercial ELISA kits were used to measure the concentrations of LL37 (HK321; Human LL-37 ELISA Kit, Hycult Biotechnology, Uden, the Netherlands) and 25(OH)D (AC-57F1; 25-hydroxy vitamin D, EIA Immunodiagnostic Systems, Scottsdale, Arizona, USA), in DMARD naïve serum samples. Levels are reported as median with (25%, 75% quartile).

Anti-cyclic citrullinated peptide (anti-CCP) antibody and rheumatoid factor {#s1-3}
---------------------------------------------------------------------------

Anti-CCP2 was measured with a commercial ELISA kit (Inova Diagnostics, San Diego, California, USA) and positivity assessed according to the manufacture's guidelines. Rheumatoid factor (RF) was measured by nephelometry in the hospital laboratory and positivity defined as RF titre \>40 IU.

HLA and VDR genotyping {#s1-4}
----------------------

HLA-DRB1 typing was performed by PCR using sequence-specific oligonucleotide primers and shared epitope (SE) bearing alleles defined as previously described.[@R13] VDR single nucleotide polymorphisms; Bsm1 (B/b (T/C)) (rs1544410), Apa1 (A/a (T/G)) (rs7975232), Taq1 (T/t (T/C)) (rs731236), Fok1 (F/f (C/T)) (rs10735810) and Cdx-2 (G/A) (rs11568820) were amplified from genomic DNA using published protocols and primers as previously described.[@R14]

Statistical analysis {#s1-5}
--------------------

Associations of serum LL37 with clinical disease and other parameters were tested using non-parametric methods. We tested the association of LL37 level (quartile) with anti-CCP positivity in logistic regression models. Model covariables were age, sex and vitamin D status measured as 25(OH)D level (deficient vs not deficient) or VDR. Subsequent models included self reported smoking status and SE status. Statistics were performed using SPSS V.24.

Results {#s2}
=======

Study participants {#s2-1}
------------------

Demographics, clinical characteristics and laboratory output of participants are shown in [table 1](#T1){ref-type="table"}. Study participants were predominantly female (70%) with a median (25th quartile; 75th quartile) age of 56 years (45,66) and 68% met criteria for RA. Nearly half (41%) of the participants were seropositive for anti-CCP of which 86% were also RF seropositive. Only 16% were seropositive for RF alone ([table 1](#T1){ref-type="table"}). Disease activity was moderate with median (25th, 75th percentile) DAS28ESR3var 3.7 (2.8, 4.8).

###### 

Demographics and clinical characteristics of study participants

                                Rheumatoid arthritis   Undifferentiated arthritis   Spondyloarthropathy
  ----------------------------- ---------------------- ---------------------------- ---------------------
  N                             123                    33                           25
  Age years                     61 (52, 68)            48 (40--53)                  46 (38.5--56)
  Sex (F)                       71%                    88%                          52%
  Anti-CCP ever positive        80/123 (65%)           2/33 (6%)                    1/25 (4%)
  RF and CCP positive           56%                    0%                           0%
  HLADRB1 SE positive           73/110 (66%)           9/27 (33%)                   8/22 (36%)
  DAS28ESR3var                  4.4 (3.2--5.2)         2.7 (1.9--3.8)               3.6 (2.9--4.5)
  mHAQ                          0.5 (0.0, 0.9)         0.2 (0--0.5)                 0.5 (0.2--1)
  Smoking status                n=102                  n=29                         n=20
   Never smoker                 34%                    31%                          40%
   Ex-smoker                    42%                    38%                          35%
   Current smoker               24%                    31%                          25%
  LL37 ng/mL                    11.8 (5.9, 24.4)       12.1 (4.1--16.0)             11.9 (3.5--18.0)
  Serum 25(OH)D mmol/L          21.5 (14.4--31.3)      17.3 (12.8--23.2)            19.6 (10.9--30.8)
  25(OH)D deficient (%)         60%                    82%                          64%
  Vit D receptor polymorphism                                                       
  Fokl                                                                              
   CC                           45/118                 15/33                        8/24
   CT                           53/118                 10/33                        11/24
   TT                           20/118                 8/33                         5/24
  Bsm1                                                                              
   TT                           28/112                 8/33                         4/23
   CT                           51/112                 14/33                        9/23
   CC                           33/112                 11/33                        10/23
  Apa1                                                                              
   TT                           26/117                 5/29                         6/24
   GT                           64/117                 16/29                        14/24
   GG                           27/117                 8/29                         4/24
  Taq1                                                                              
   TT                           42/117                 12/29                        12/24
   TC                           59/117                 15/29                        11/24
   CC                           16/117                 2/29                         1/24
  Cdx1                                                                              
   GG                           0/52                   0/14                         0/14
   GA                           52/52                  14/14                        14/14
   AA                           0/52                   0/14                         0/14

Categorical variables are reported as n/N measured (%), continuous variables are median (25%, 75%)±range.

CCP, cyclical citrullinated peptide; RF, rheumatoid factor; SE, shared epitope.

Serum LL-37, 25(OH)D, anti-CCP {#s2-2}
------------------------------

Serum LL37 levels varied widely (median LL37 11.8 ng/mL \[5.9, 22.3\]) but were similar across RA, UA or SpA (median \[25%, 75%; range\]; RA 11.8 ng/mL \[5.9,24.4; 0--2303\], UA 12.1 ng/mL \[4.1,16.0; 0--34.7\]; SpA 11.9 ng/mL \[3.5,18.0; 0--4050\], p=0.4) ([table 1](#T1){ref-type="table"}). Therefore, subsequent analyses combined all three diagnostic categories. All participants had low serum 25(OH)D (median \[25%, 75%; range\]); 20.5 (20.4 nmol/L \[13.6--29; 4.1--63.1\]) and 64% of participants were vitamin D deficient with serum levels of 25(OH)D \<25 nmol/L. LL37 and 25OH vitD levels did not correlate (rho −0.1, p=0.2). LL37 and anti-CCP2 titres correlated (rho 0.3, p\<0.0001).

Multivariable models for independent association of LL-37 with anti-CCP {#s2-3}
-----------------------------------------------------------------------

We tested the association of serum levels of LL-37 with anti-CCP using logistic regression models controlling for age, sex and vitamin D deficiency ([table 2](#T2){ref-type="table"}). Top quartile serum LL-37 was associated with positive anti-CCP status (OR 6.3 \[CI 2.4 to 17.0\]). The association of LL37 and anti-CCP remained significant when smoking and SE allele status were included in the model. Similar findings were seen when vitamin D status was assessed by VDR genotype, or when models included arthritis diagnosis (data not shown).

###### 

Association of LL37 level and anti-CCP antibody status\*

  Model                     OR     95% CI OR
  ------------------------- ------ ------------
  **Model 1**                      
  Age                       1      1.0--1.1
  Gender (female)           1      0.4--2.1
  Vitamin D deficient†      1.4    0.7--2.8
  LL37                             
   LL37 Q1                  Ref    --
   LL37 Q2                  2.7    1.0--6.9
   LL37 Q3                  1.6    0.6--4.4
   LL37 Q4                  6.3    2.4--17.0
                                   
  **Model 2**                      
  Age                       1      1.0--1.0
  Gender (female)           0.5    0.2--1.5
  Vitamin D deficient†      2.2    0.8--5.9
  Smoking status                   
   Never                    Ref    
   Quit                     2.3    0.8--6.6
   Current                  3.4    1.0--11.8
  Shared epitope positive   5.2    1.8--14.5
  LL37                             
   LL37 Q1                  Ref    
   LL37 Q2                  9.1    2.0--41.4
   LL37 Q3                  3.2    0.7--14.7
   LL37 Q4                  22.1   4.7--104.1

\*Dependent variableanti-CCP seropositive status.

†Similar findings whenvitamin D status was assessed as vitamin D receptor haplotype (Fokl, Bsm, Apa orTaq).

Q, quartile; ref, reference category.

Association of LL-37 with clinical variables and VDR polymorphisms {#s2-4}
------------------------------------------------------------------

LL-37 levels did not correlate with clinical disease activity (DAS28ESR3var Spearmans rho 0.07, p=0.4; ESR rho 0.04, p=0.6; swollen 28 joint count rho 0.1, p=0.1), mHAQ (rho 0.03, p=0.7) or with self-reported smoking (never \[11.2 ng/mL; 4.9, 21.8; 0--4050\], past \[11.9 ng/mL; 7.2, 21.8; 0--1469.2\], current \[14.2 ng/mL; 8.6, 47.9; 0--2303\], Kruskal-Wallis test p=0.4). The distribution of VDR polymorphisms (Fok1, BsM1, ApA1, Taq, Cdx1) was similar across the three diagnostic groups (RA, UA and SpA) ([table 1](#T1){ref-type="table"}) and 25(OH)D levels were similar across the different VDR polymorphisms (data not shown). HLA-DRB1 SE positivity was associated with anti-CCP (OR 5.2; CI 1.8 to 14.5) however, no associations were seen between LL-37 and HLA-DRB1 SE or VDR receptor polymorphisms ([table 3](#T3){ref-type="table"}). Similar findings were observed in analyses including only RA subjects (data not shown).

###### 

Circulating levels of LL-37 based on antibody shared epitope and vitamin D status

  --------------------------------- ------------------------------ -----------
  Anti-CCP negative                 10.9 (4.1, 16.7) 0--4050.2     P=0.001
  Anti-CCP positive                 17.1 (8.7, 43.3) 0--2303.1     
  RF negative                       10.4 (3.8, 14.3) 0--4050.2     P=0.001
  RF positive                       16.6 (8.2, 30.5) 0--2303.1     
  Number of autoantibodies                                         
   RF and anti-CCP negative         10.4 (3.8, 13.9) 0--4050.2     P\<0.0001
   RF or anti-CCP positive          10.9 (5.4, 23.4) 0--1073.4     
   RF and anti-CCP positive         17.4 (9.24, 47.7) 0--2303.1    
  Shared epitope positive           11.8 (6.1, 23.7) 0--2303       P=0.5
  Shared epitope negative           10.9 (4.1, 21.5) 0--4050.2     
  25(OH)D \<25 nmol/L (deficient)   12.2 (7.2, 25.3) 0--4050.2     P=0.08
  25(OH)D \>25 nmol/L (adequate)    10.9 (4.1, 19.9) 0--1469.2     
  Smoking status                                                   
   Never smoked                     11.2 (4.9, 21.9)0.1--4050.2    P=0.4
   Quit smoking                     11.9 (7.2, 21.8) 0--1469.2     
   Current smoking                  14.2 (8.6, 47.9) 0--2303.1     
  Vit D receptor polymorphism                                      
  Fokl                              10.6 (5.3, 24.7) 0--2303       P=1.0
   CC                               11.9 (5.0, 21.6) 0.1--4050.1   
   CT                               12.3 (6.8, 19.4) 0--1469.2     
   TT                                                              
  Bsm1                              11.6 (8.5, 17.1) 0.2--550.8    P=0.3
   TT                               13.4 (6.5, 23.6) 0--4050.2     
   CT                               9.6 (4.1, 21.0) 0--1469.2      
   CC                                                              
  Apa1                              11.6 (7.4, 17.1) 0.23--550.8   P=1.0
   TT                               11.6 (5.0, 26.0) 0--4050.2     
   GT                               11.9 (4.9, 22.3) 0--1469       
   GG                                                              
  Taq1                              10.2 (4.7, 22.0) 0--1469.2     P=0.8
   TT                               11.9 (5.5, 23.9) 0--4050.2     
   TC                               12.5 (8.8, 17.3) 0.2--550.8    
   CC                                                              
  --------------------------------- ------------------------------ -----------

Median (25th, 75th quartile) (range) reported. Statistical significance determined using Man-Whitney U non-parametric two group comparison or Kruskal-Wallis test for three group comparison.

CCP, cyclical citrullinated peptide; RF, rheumatoid factor.

Discussion {#s3}
==========

Cathelicidin LL37 expression is associated with anti-CCP seropositivity in patients with DMARD naïve EIA, however, serum LL37 levels do not associate with common VDR polymorphisms, circulating vitamin D or articular activity.

Several lines of evidence support a role for LL37 in autoimmune disease.[@R15] In lupus and psoriasis, LL-37 increases immunogenicity and stability of DNA facilitating plasmacytoid dendritic cell activation. Autoantibodies directed to LL37-DNA complexes are detected in multiple organs of lupus patients.[@R6] In psoriasis, LL37 is an autoantigen for pathogenic T helper cells and circulating levels are elevated over healthy controls but do not correlate with skin activity.[@R16] In psoriatic arthritis, synovial fluid has elevated LL37 protein levels and antibodies to carbamylated LL37, but not citrullinated LL37, correlate with articular disease activity.[@R7] In RA, LL37 and C1q enhance NET induced macrophage activation,[@R4] LL37 protein expression is elevated in serum and synovium[@R17] but, as in this report, serum levels of LL37 protein are not correlated with disease activity and neither are antibodies to LL37.[@R18] LL37 induces induced osteoblast apoptosis,[@R19] suggesting potential to contribute to arthritis associated osteopenia. We report the association of elevated levels of LL37 with anti-CCP seropositivity in EIA.

The observed association of LL-37 with anti-CCP may reflect exposure to infectious or non-infectious factors implicated in RA pathogenesis and host responses. LL37 contributes to innate anti-microbial defences and although it is unclear if LL-37 citrullination occurs in vivo, citrullination of LL37 impairs its anti-infective activities in vitro[@R20] potentially increasing bacterial burden. In periodontal disease, a known risk factor for RA, LL37 gingival levels are elevated and RA-like hypercitrullination develops in neutrophils exposed to pore forming toxins produced by *A actinomycetemcomitans,* a periodontal pathogen associated with ACPA positive RA.[@R21] Smoking induced damage associated molecular pattern responses are enhanced by LL37 in patients predisposed to non-rheumatic lung disease.[@R24] Thus, LL37 may partly mediate immune responses relevant to RA that are induced from interactions between environmental factors and articular or non-articular host tissues.

Vitamin D has multiple effects on immune mechanisms and cellular metabolism potentially relevant for autoimmunity[@R9] and is important for LL37 expression.[@R10] However, we did not find robust associations of LL37 with serum 25OHvitD or VDR polymorphisms, even though both have been associated with RA in some populations. This may reflect uniform vitamin D insufficiency in our cohort, the small sample size or the VDR polymorphisms tested. Of the polymorphisms tested only Fok1 leads to functional changes in the receptor whereas the functional implications of the other polymorphisms are less clear; other VDR polymorphisms may be relevant to LL37 expression. However, metabolic stress independent of vitamin D can induce LL37 expression.[@R25] Alternatively, preformed LL37, or reduced LL37 degradation, may be sufficient to generate autoimmune responses. Data to support this are needed.

Our study has limitations. Samples were obtained in subjects with new onset arthritis prior to instituting immunomodulatory therapy. In this study, we cannot assess the trajectory of LL37 during the preclinical disease phase or after therapy. Our analysis of serum vitamin D is limited as all participants had low levels. We combined different arthropathies due to small sample sizes however, results were similar when we limited the analysis to only RA. Although the HK321 LL-37 ELISA does not discriminate between LL-37 and the precleaved hCAP18 protein, in general hCAP18 is restricted to intracellular granules thus in circulation the assay reflects LL37 protein.

In this cohort of EIA, cathelicidin (LL37) levels associate with seropositivity to anti-CCP, further supporting the role of LL37 in development of inflammatory arthritis.
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